uniQure N.V.
News
Institutional owners may take dramatic actions as uniQure N.V.'s (NASDAQ:QURE) recent 11% drop adds to one-year losses
Simply Wall St Key Insights Significantly high institutional ownership implies uniQure's stock price is sensitive to their trading...\n more…
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
Globe Newswire LEXINGTON, Mass. and AMSTERDAM, Aug. 15, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...\n more…
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Simply Wall St uniQure N.V. ( NASDAQ:QURE ) just released its quarterly report and things are looking bullish. Overall results were...\n more…
QURE Stock Earnings: uniQure Beats EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nQURE stock results show that uniQure beat analyst estimates for earnings per share and beat on revenue for the second quarter of...\n more…
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
Globe Newswire ~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of...\n more…
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
Globe Newswire ~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40...\n more…